Related coverage linked through entity extraction aliases.
Feb 17, 2026
Eli Lilly reported Q4 2025 EPS of $7.54 versus $6.67 expected and projected 2026 revenue of $80-83 billion. The company's GLP-1 drugs Mounjaro and Zepbound drove growth with revenues surging over 110%.
Feb 16, 2026
Eli Lilly committed $1 billion to build an AI-powered supercomputer with Nvidia for drug discovery, launching its TuneLab platform in September and establishing a co-innovation lab by January.
Feb 14, 2026
Life sciences companies are integrating AI into clinical trial operations to reduce administrative burden and improve efficiency, while the biotechnology sector experiences a structural transformation driven by AI industrialization and institutional capital.
Feb 14, 2026
Pharmaceutical companies are deploying AI and machine learning across clinical trial execution, regulatory submissions, and drug discovery to address rising costs and lengthy timelines in drug development.
Feb 13, 2026
Artificial intelligence is accelerating drug discovery from molecule screening to clinical trials, but legal uncertainty over patent ownership and profit distribution threatens to slow progress as the technology reshapes pharmaceutical development.
Feb 13, 2026
Eli Lilly has accumulated $1.5 billion in pre-launch inventory of its experimental oral weight-loss drug orforglipron ahead of an expected FDA decision in April, up from $550 million last year.
